Gyon Technologies Capital Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Gyon Technologies Capital Management’s Portfolio SNDX Stock Details SNDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-68,195	Closed	-$1.74M	–	353
2022 Q4	$1.74M	Buy	68,195 +35,226	+107%	+$822K	0.65%	44
2022 Q3	$792K	Sell	32,969 -45,213	-58%	-$1.01M	0.25%	110
2022 Q2	$1.5M	Buy	78,182 +30,929	+65%	+$515K	0.42%	78
2022 Q1	$821K	Sell	47,253 -43,681	-48%	-$735K	0.58%	54
2021 Q4	$1.99M	Sell	90,934 -1,451	-2%	-$26.8K	0.37%	72
2021 Q3	$1.76M	Buy	+92,385	New	+$1.54M	0.48%	72
2021 Q1	–	Sell	-9,478	Closed	-$211K	–	502
2020 Q4	$211K	Buy	+9,478	New	+$197K	0.07%	308

Other funds holding SNDX

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

APM

Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Gyon Technologies Capital Management's SNDX Position: Q1 2023 in Review

Gyon Technologies Capital Management sold out of Syndax Pharmaceuticals (SNDX) in Q1 2023, closing a stake of 68,195 shares — an estimated $1.74M sold.

Gyon Technologies Capital Management first reported a position in SNDX in Q4 2020 and held it in 7 quarters. The position peaked at $1.99M in Q4 2021. 163 funds tracked by Wall St. Rank hold SNDX as of Q1 2023.

Gyon Technologies Capital Management reported no remaining Syndax Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
Gyon Technologies Capital Management sold 68,195 Syndax Pharmaceuticals shares in Q1 2023, an estimated $1.74M.
Gyon Technologies Capital Management first reported a position in Syndax Pharmaceuticals in Q4 2020 and held it in 7 quarters.
Gyon Technologies Capital Management's Syndax Pharmaceuticals position peaked at $1.99M in Q4 2021.
163 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q1 2023.

Based on Gyon Technologies Capital Management's 13F filing for Q1 2023.